Published October 3, 2019
| Version v1
Patent
Open
IL13Ralpha2 Binding Agents and Use Thereof in Cancer Treatment
Contributors
Patent applicant:
Description
Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).
Files
US20190300616.pdf
Files
(5.5 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:a172179f386419110324d2732bbd0935
|
5.5 MB | Preview Download |
Additional details
Identifiers
- Patent number
- US 2019/0300616 A1
- Patent application number
- US 201916385853 A
- Other
- oai:uchicago.tind.io:6684
Dates
- Patent filed
-
2019-04-16